衰弱老年人双膦酸盐治疗期间髋部骨折预测因素
结果显示双膦酸盐使用者与降钙素使用者的髋部骨折预测因素无差异,提示骨折预防应超越药物治疗、尤其重视跌倒预防。
要点
- 双膦酸盐使用者与降钙素使用者的髋部骨折预测因素无差异。
- 年龄75至85岁、女性、白人、BMI 18.5–24.9与髋部骨折风险升高相关。
- 独立转移能力和偶发尿失禁也是重要预测因素,痴呆和糖尿病未显示关联。
核心结论
- 衰弱老年人中,双膦酸盐新使用者与降钙素新使用者的髋部骨折预测因素无差异,未发现双膦酸盐使用者特有的危险因素。
- 骨折预防策略应超越药物治疗,纳入现有非药物疗法,尤其跌倒预防策略。
研究设计与样本
- 回顾性队列研究,使用2008—2013年链接的美国国家最小数据集评估、医疗保险索赔和养老院设施数据。
- 住院髋部骨折结局通过Part A索赔测量,对36项预设潜在预测因素估计风险比(HR)和95%置信区间(CI)。
主要发现
- 研究人群平均(SD)年龄84(8)岁,85%为女性,51%有中度至重度认知障碍。
- 双膦酸盐使用期间髋部骨折风险升高的预测因素包括年龄75至85岁(对比65至<75岁;HR=1.25;95%CI=1.02-1.55)。
- 女性(HR=1.33;95%CI=1.06-1.67)、白人(对比黑人;HR=1.87;95%CI=1.36-2.58)、BMI 18.5-24.9(对比≥30;HR=1.93;95%CI=1.53-2.42)与髋部骨折风险升高相关。
- 独立转移能力(对比完全依赖;HR=3.11;95%CI=1.83-5.30)和偶发尿失禁(对比频繁;HR=1.45;95%CI=1.18-1.78)也是重要预测因素。
- 痴呆、糖尿病、精神药物使用及其他特征与处方后髋部骨折无关联,预测因素在双膦酸盐与降钙素使用者间无差异。
临床怎么用
- 对启动双膦酸盐的衰弱老年人,应同时评估年龄、性别、BMI、转移能力和尿失禁等骨折预测因素。
- 骨折预防不应仅依赖药物,应扩展至非药物疗法,尤其跌倒预防策略。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Bisphosphonates are effective at preventing hip fractures among older adults, yet many patients still fracture while on treatment and may benefit from additional preventive interventions. Little data are specifically available to target such efforts among bisphosphonate users. We aimed to identify predictors of hip fracture unique to frail older adults initiating pharmacologic treatment for osteoporosis. DESIGN: Retrospective cohort using 2008-2013 linked national Minimum Data Set assessments, Medicare claims, and nursing home (NH) facility data. SETTING: NHs in the United States. PARTICIPANTS: Long-stay NH residents 65 years or older who initiated treatment with a bisphosphonate (N = 17 753). Estimates for bisphosphonate initiators were contrasted with those for calcitonin initiators (control group; N = 5348). MEASUREMENTS: Hospitalized hip fracture outcomes were measured using Part A claims. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for 36 a priori selected potential predictors. RESULTS: The mean (SD) age of the study population was 84 (8) years, 85% were women, and 51% had moderate to severe cognitive impairment. Predictors associated with a higher risk of hip fracture despite bisphosphonate use included age 75 years or older to 85 years (vs ≥65 to <75 y; HR = 1.25; 95% CI = 1.02-1.55), female sex (HR = 1.33; 95% CI = 1.06-1.67), white race (vs black race (HR = 1.87; 95% CI = 1.36-2.58), and body mass index = 18.5-24.9 (vs ≥30; HR = 1.93; 95% CI = 1.53-2.42). Independent ability to transfer (vs total dependence; HR = 3.11; 95% CI = 1.83-5.30) and occasional urinary incontinence (vs frequent; HR = 1.45; 95% CI = 1.18-1.78) were also important predictors. Dementia, diabetes, psychoactive drug use, and other characteristics were not associated with post-prescribing hip fracture. Predictors did not differ between bisphosphonate and calcitonin users. CONCLUSION: Predictors of hip fracture among frail older adults did not differ between those who were new users of bisphosphonates vs calcitonin. Given the absence of risk factors unique to bisphosphonate users, targeting of fracture prevention efforts should extend beyond pharmacologic therapy to include existing nonpharmacologic therapies, particularly fall prevention strategies. J Am Geriatr Soc 68:256-260, 2020.
引用
- Zullo AR, Sorial MN, Lee Y, et al. Predictors of Hip Fracture Despite Treatment with Bisphosphonates among Frail Older Adults. J Am Geriatr Soc. 2019. PMID: 31580488. doi:10.1111/jgs.16176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。